All In Biotech

Drug Trial Radar · NCT02891850

Riociguat rEplacing PDE-5i Therapy evaLuated Against Continued PDE-5i thErapy

A Prospective, Randomized, International, Multicenter, Double-arm, Controlled, Open-label Study of Riociguat in Patients With Pulmonary Arterial Hypertension (PAH) Who Are on a Stable Dose of Phosphodiesterase-5 Inhibitors (PDE-5i) With or Without Endothelin Receptor Antagonist (ERA), But Not at Treatment Goal

Last checked: Nov 20, 2026Latest source record: Feb 26, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 225 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

225

Actual

Start

Jan 11, 2017

Primary completion

Jan 29, 2020

Study completion Mar 3, 2020

Sponsor

Lead sponsor
BayerBayer (BAYRY)
Sponsor type
Industry
First posted
Sep 8, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To demonstrate the effectiveness of riociguat as replacement of phosphodiesterase-5 inhibitors (PDE-5i) therapy in pulmonary arterial hypertension (PAH) patients

Conditions

  • Pulmonary Arterial Hypertension

Interventions

  • Riociguat (Adempas, BAY63-2521)Drug

    Film-coated tablets will be used in this study at a dosage of 0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg. Tablets will be administered orally.The starting dose is 1 mg TID; the intervals between drug intakes should be 6 to 8 hours. The dosage should be increased by 0.5 mg increments in 2 week intervals to 1.5 mg, 2.0 mg, and 2.5 mg TID (maximal total daily dose).

  • SildenafilDrug

    Patients randomized to the control arm will continue to receive stable doses of tadalafil (daily dose 20 to 40 mg) or sildenafil (daily dose at least 60 mg) as well as other supportive treatments at the discretion of the investigator.

  • TadalafilDrug

    Patients randomized to the control arm will continue to receive stable doses of tadalafil (daily dose 20 to 40 mg) or sildenafil (daily dose at least 60 mg) as well as other supportive treatments at the discretion of the investigator.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Satisfactory Clinical Response at Week 24Time frame: At Week 24

Locations

81 sites in 21 countries. Site status is shown where the registry gives one.

  • Site not named

    Phoenix, Arizona

  • Site not named

    Tucson, Arizona

  • Site not named

    Sacramento, California

  • Site not named

    Orlando, Florida

  • Site not named

    Weston, Florida

  • Site not named

    Kansas City, Kansas

  • Site not named

    Louisville, Kentucky

  • Site not named

    Detroit, Michigan

  • Site not named

    Troy, Michigan

  • Site not named

    Newark, New Jersey

  • Site not named

    Mineola, New York

  • Site not named

    New York, New York

  • Site not named

    Rochester, New York

  • Site not named

    Cleveland, Ohio

  • Site not named

    Nashville, Tennessee

  • Site not named

    Dallas, Texas

  • Site not named

    Richmond, Virginia

  • Site not named

    Graz, Austria

  • Site not named

    Leuven, Belgium

  • Site not named

    São Paulo, Brazil

  • Site not named

    São Paulo, Brazil

  • Site not named

    Belo Horizonte, Minas Gerais, Brazil

  • Site not named

    Belo Horizonte, Minas Gerais, Brazil

  • Site not named

    Porto Alegre, Rio Grande do Sul, Brazil

  • Site not named

    Blumenal, Santa Catarina, Brazil

  • Site not named

    Montreal, Quebec, Canada

  • Site not named

    Prague, Czechia

  • Site not named

    Prague, Czechia

  • Site not named

    Aarhus N, Denmark

  • Site not named

    Le Kremlin-Bicêtre, France

  • Site not named

    Rouen, France

  • Site not named

    Berlin, Germany

  • Site not named

    Giessen, Germany

  • Site not named

    Hamburg, Germany

  • Site not named

    Heidelberg, Baden-Wurttemberg, Germany

  • Site not named

    München, Bavaria, Germany

  • Site not named

    München, Bavaria, Germany

  • Site not named

    Würzburg, Bavaria, Germany

  • Site not named

    Hanover, Lower Saxony, Germany

  • Site not named

    Cologne, North Rhine-Westphalia, Germany

Showing 40 of 81 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.